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IMPORTANCE Genetic studies have evaluated the influence of blood lipid levels on the risk of
coronary artery disease (CAD), but less is known about how they are associated with the
extent of coronary atherosclerosis.
OBJECTIVE To estimate the contributions of genetically predicted blood lipid levels on the
extent of coronary atherosclerosis.
DESIGN, SETTING, AND PARTICIPANTS This genetic study included Icelandic adults who had
undergone coronary angiography or assessment of coronary artery calcium using cardiac
computed tomography. The study incorporates data collected from January 1987 to
December 2017 in Iceland in the Swedish Coronary Angiography and Angioplasty Registry
and 2 registries of individuals who had undergone percutaneous coronary interventions and
coronary artery bypass grafting. For each participant, genetic scores were calculated for
levels of non–high-density lipoprotein cholesterol (non–HDL-C), low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides, based
on reported effect sizes of 345 independent, lipid-associated variants. The genetic scores’
predictive ability for lipid levels was assessed in more than 87 000 Icelandic adults. A
mendelian randomization approach was used to estimate the contribution of each lipid trait.
EXPOSURES Genetic scores for levels of non–HDL-C, LDL-C, HDL-C, and triglycerides.
MAIN OUTCOMES AND MEASURES The extent of angiographic CAD and coronary artery
calcium quantity.
RESULTS A total of 12 460 adults (mean [SD] age, 65.1 [10.7] years; 8383 men [67.3%])
underwent coronary angiography, and 4837 had coronary artery calcium assessed by
computed tomography. A genetically predicted increase in non–HDL-C levels by 1 SD (38
mg/dL [to convert to millimoles per liter, multiply by 0.0259]) was associated with greater
odds of obstructive CAD (odds ratio [OR], 1.83 [95% CI, 1.63-2.07]; P = 2.8 × 10−23). Among
patients with obstructive CAD, there were significant associations with multivessel disease
(OR, 1.26 [95% CI, 1.11-1.44]; P = 4.1 × 10−4) and 3-vessel disease (OR, 1.47 [95% CI, 1.26-1.72];
P = 9.2 × 10−7). There were also significant associations with the presence of coronary artery
calcium (OR, 2.04 [95% CI, 1.70-2.44]; P = 5.3 × 10−15) and loge-transformed coronary artery
calcium (effect, 0.70 [95% CI, 0.53-0.87]; P = 1.0 × 10−15). Genetically predicted levels of
non–HDL-C remained associated with obstructive CAD and coronary artery calcium extent
even after accounting for the association with LDL-C. Genetically predicted levels of HDL-C
and triglycerides were associated individually with the extent of coronary atherosclerosis,
but not after accounting for the association with non–HDL cholesterol.
CONCLUSIONS AND RELEVANCE In this study, genetically predicted levels of non–HDL-C were
associated with the extent of coronary atherosclerosis as estimated by 2 different methods.
The association was stronger than for genetically predicted levels of LDL-C. These findings
further support the notion that non–HDL-C may be a better marker of the overall burden of
atherogenic lipoproteins than LDL-C.
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L ow-density lipoprotein cholesterol (LDL-C) is an estab-lished risk factor for coronary artery disease (CAD).1Traditionally, LDL-C has been regarded as the primary
marker of atherogenic lipoproteins and a treatment target for
lipid-lowering therapies.1 However, there is growing evi-
dence that LDL-C may not be the best marker of the cardio-
vascular risk conferred by atherogenic lipoproteins. Epide-
miological studies2-6 have shown that non–high-density
lipoprotein cholesterol (non–HDL-C) and apolipoprotein B,
which are highly correlated, are superior to LDL-C for cardio-
vascular risk prediction in healthy individuals and patients
with coronary disease. Experimental evidence from clinical
trials7-9 shows that aggressive lowering of LDL-C can slow pro-
gression and even induce regression of coronary atheroscle-
rosis, as assessed by intravascular ultrasonography. A recent
analysis of clinical trial data,10 however, showed that changes
in coronary atheroma volume may be more closely associ-
ated with levels of non–HDL-C than LDL-C.
Mendelian randomization is a method in which genetic
information is used to infer whether an exposure is causally
associated with an outcome (eg, a disease).11 Using this method,
genetic studies1 have supported a potential causal role of
LDL-C in coronary disease, but few have assessed non–
HDL-C directly.12 In a previous study using mendelian
randomization,13 we provided evidence to support a poten-
tial causal role of non–HDL-C in coronary diseases and showed
that genetically predicted non–HDL-C levels were more sig-
nificantly associated than LDL-C was with risk of CAD. Al-
though genetic scores for lipid levels have been widely stud-
ied in the context of cardiovascular risk, less is known about
their association with measures of the extent of coronary ath-
erosclerosis. To our knowledge, 2 studies14,15 have associated
genetic scores for lipid levels with the extent of coronary ath-
erosclerosis. Both studies evaluated associations with coro-
nary artery calcium (CAC), a noninvasive marker of the over-
all coronary atherosclerotic burden.16 A genetic score for LDL-C
was associated with higher CAC in one study14 but not the
other.15 In addition, one of the studies14 evaluated genetic
scores for HDL-C and triglyceride levels and did not find sig-
nificant associations with CAC. In the present study, we used
mendelian randomization to evaluate the contributions of in-
dividual lipid traits on the extent of coronary atherosclerosis
in a data set of Icelandic adults undergoing coronary angiog-
raphy and evaluation of CAC.
Methods
Study Participants
We identified Icelandic adults who had undergone coronary
angiography for any indication at Landspítali–The National Uni-
versity Hospital in Reykjavík, the only interventional cardiol-
ogy center in Iceland. The data were obtained from 3 clinical
registries, as described previously.17 First was the Swedish
Coronary Angiography and Angioplasty Registry (SCAAR),
which holds data on all consecutive individuals undergoing
coronary angiography and percutaneous coronary interven-
tion in Iceland since January 1, 2007.18,19 From SCAAR, we
obtained data collected prospectively between January 1, 2007,
and December 31, 2017 (including 13 437 procedures for 9885
adults who had been genotyped). Second, we used a registry
of all percutaneous coronary intervention procedures per-
formed in Iceland between January 1, 1987, and December 31,
2006 (including 5386 procedures for 3743 patients who had
been genotyped). Finally, we used a registry of coronary-
artery bypass grafting procedures performed in Iceland, which
holds data on patients who underwent preprocedural coro-
nary angiography between January 1, 2001, and December 31,
2013 (1309 procedures for 1309 patients who had been
genotyped).20 For the main analyses, the 3 data sources were
combined into a single data set (eFigure 1 in the Supplement);
for individuals with multiple procedures, we only used the
earliest record (n = 12 728 unique individuals). Information
on cardiovascular risk factors was obtained from these regis-
tries. In the combined data set, hypertension, diabetes, and
hyperlipidemia were defined by previous diagnosis of the
respective condition or medical treatment at the time of angi-
ography (with antihypertensive, antidiabetic, or lipid-
lowering medication, respectively). Individuals with missing
data were removed prior to analyses (n = 268), resulting in a
total sample size of 12 460.
We identified Icelandic adults who underwent cardiac com-
puted tomography for any indication at Röntgen Domus, the
largest privately operated medical imaging clinic in the coun-
try. Imaging was performed between January 4, 2009, and Oc-
tober 31, 2017. A CAC score (Agatston score)21 was available for
4837 individuals who had been genotyped. For each indi-
vidual, we used the earliest record only. Information on car-
diovascular risk factors, other than age at the time of proce-
dure and sex, was not available. All participants donated
samples for genotyping and provided informed consent as part
of various genetic programs at deCODE genetics. The study was
approved by the Data Protection Authority of Iceland and the
National Bioethics Committee of Iceland. Personal identities
of the participants were encrypted with a third-party system
provided by the Data Protection Authority of Iceland.
Coronary Angiography
Coronary angiograms were evaluated by the interventional car-
diologists performing the procedures. Angiographic extent of
Key Points
Question Are genetically predicted lipid levels associated with
the extent of coronary atherosclerosis?
Findings This study found that a genetic score for
non–high-density lipoprotein cholesterol was significantly
associated with the extent of coronary atherosclerosis, as
estimated by coronary angiography or coronary calcium scanning
in Icelandic adults. The association persists after accounting for
low-density lipoprotein cholesterol.
Meaning Elevated non–high-density lipoprotein cholesterol is
associated with the development of coronary atherosclerosis and
may be a better marker for atherogenic lipoproteins than
low-density lipoprotein cholesterol.
Research Original Investigation Association of Genetically Assessed Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults
14 JAMA Cardiology January 2020 Volume 5, Number 1 (Reprinted) jamacardiology.com
Downloaded From: https://jamanetwork.com/ on 02/04/2020
CAD was quantified as the number of major epicardial coro-
nary arteries (the left anterior descending artery, the circum-
flex artery, or the right coronary artery) with at least 50%
luminal diameter stenosis (significant stenosis), ranging from
0 to 3 diseased coronary arteries. Obstructive CAD was de-
fined as having 1 to 3 coronary arteries with significant steno-
sis or significant stenosis in the left main coronary artery. No
or nonobstructive CAD was defined as having less than 50%
stenosis in all 3 major coronary arteries and the left main coro-
nary artery. Patients with obstructive CAD and without left
main disease were categorized as having 1-vessel, 2-vessel, or
3-vessel disease, based on the number of coronary arteries with
significant stenosis. Those with left main disease were cat-
egorized separately. Multivessel disease was defined as hav-
ing 2-vessel or 3-vessel disease or left main disease.
Quantification of Coronary Artery Calcium
Coronary artery calcium was assessed using cardiac-gated mul-
tidetector computed tomography scanners (Aquilion [Toshiba
Medical Systems]) with a slice thickness of 0.5 to 3 mm. Scans
were read by radiologists, and CAC was quantified using a CAC
score (Agatston score).21
Genotyping and Imputation
Genotyping and imputation methods were as previously
described.22,23 Briefly, DNA sequence variants identified in the
genomes of 28 075 Icelandic adults whose whole genomes have
been sequenced were imputed into 155 250 Icelanders who had
been genotyped using various Illumina single-nucleotide poly-
morphism chips and their genotypes phased using long-
range phasing.22-24
Genetic Scores
We constructed individual-level genetic scores for levels of
non–HDL-C, LDL-C, HDL-C, and triglycerides based on vari-
ants identified in a recent large-scale, exome-wide associa-
tion study of lipid levels.25 That study reported 444 single-
nucleotide polymorphisms in 250 loci with minor allele
frequency ranging from 6.7 × 10−6 to 0.49. Each variant was
reported to associate independently with at least 1 lipid
level (total cholesterol, LDL-C, HDL-C, or triglycerides) at
P < 2.1 × 10−7, a Bonferroni correction for the testing of 242 289
variants. In our study, a total of 414 variants were observed in
the population that had been genotyped (n = 155 250), of which
412 had good imputation quality (imputation information of
at least 0.90); 2 variants with imputation information less than
0.90 were excluded (eTable 1 in the Supplement). For the cal-
culation of the genetic scores, to minimize potential bias as-
sociated with including correlated variants, we used a subset
of 345 variants with pairwise r2 less than 0.20 (eTable 1 in the
Supplement). Based on this set, we calculated the genetic
scores by summing the product of the allele count and the cor-
responding effect size for each variant. A flowchart summa-
rizing the selection of variants and calculation of the genetic
scores is presented in eFigure 2 in the Supplement.
For the genetic scores for LDL-C, HDL-C, and triglycer-
ides, we used the effect sizes (with SDs) as previously
reported25; these were estimated by using data from more than
300 000 Europeans, of whom less than 1% were Icelandic. Be-
cause association results for non–HDL-C were not available
from this resource, we used the reported effect sizes for total
cholesterol and HDL-C to derive effect sizes for non–HDL-C.
To generate an equation to estimate the association with non–
HDL-C, we analyzed the lipid effect sizes of 48 463 variants with
minor allele frequency greater than 1.0% that were associ-
ated with each lipid trait at P values less than .05 in the Ice-
landic population (sample sizes: 93 556, 103 599, and 93 746
individuals for non–HDL-C, total cholesterol, and HDL-C, re-
spectively). Ordinary least-squares regression estimated the
non–HDL-C effect size as 0.979 × total cholesterol effect
size – 0.354 × HDL-C effect size (with all effect sizes in SDs, es-
timated on inverse normal-transformed values). There was a
high correlation between estimated and observed effect sizes
on non–HDL-C (R2 = 0.99). This equation had high predictive
accuracy (R2 = 0.93) in an external validation sample from the
UK Biobank26 (eMethods in the Supplement), using a set of
50 000 randomly selected variants with minor allele fre-
quency greater than 1.0% and effect sizes based on cholesterol
measurements for more than 358 000 individuals. Thus, the ef-
fect sizes of variants on non–HDL-C can be reliably predicted
from their associations with total cholesterol and HDL-C, con-
sistent with the fact that non–HDL-C is calculated directly from
these lipid measurements (total cholesterol level − HDL-C level).
We used this equation to estimate effect sizes for non–HDL-C
from the effect sizes for total cholesterol and HDL-C levels, as
previously reported,25 and used the estimated effect sizes for
calculation of the genetic score for non–HDL-C. Effect sizes used
for the calculation of the genetic scores are shown in eTable 1
in the Supplement.
Each genetic score was associated with its respective
lipid level in samples of more than 87 000 Icelandic adults
for whom genotyping was performed (eMethods and
eTable 2 in the Supplement). The genetic score for non–
HDL-C explained 12.8% of the variance in non–HDL-C levels.
For LDL-C, HDL-C, and triglycerides, the variance explained
by the corresponding genetic score was 13.1%, 11.3%, and
8.9%, respectively (eTable 2 in the Supplement). The genetic
scores showed weak to moderate pairwise correlation, with
the exception of the genetic scores for non–HDL-C and




We used a mendelian randomization approach involving ge-
netic scores as instrumental variables to infer potential causal
contributions of individual lipid traits. Because of the pleiot-
ropy of lipid-associated variants (ie, each variant being com-
monly associated with more than 1 lipid level25), the associa-
tion of a genetic score for a given lipid level may be confounded
by its correlation with other lipid levels. To account for these
pleiotropic effects, we conducted joint analyses in which the
association of a given genetic score (eg, for LDL-C) was ad-
justed for genetic scores for other lipid levels (eg, for HDL-C
and triglycerides) by including them as covariates in the model.
Recently, we applied this approach in another mendelian ran-
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domization study to infer the potential causal role of lipid lev-
els in the context of risk of coronary disease.13
Association Analyses
We used logistic regression models to test for associations with
dichotomized measures of angiographic extent of CAD and CAC.
Linear regression models were used to test for associations with
CAC as a continuous variable as the natural logarithm of the CAC
score plus 1 (loge[CAC score +1]). Association analyses involv-
ing angiographic extent of CAD were adjusted for age, age2, sex,
diabetes, hypertension, and current and former smoking sta-
tus. Results did not differ materially when adjusted only for
age, age2, and sex (eTable 4 in the Supplement). Association
analyses of CAC were adjusted for age, age2, and sex. Unless oth-
erwise noted, effect size estimates for the genetic scores were
scaled to correspond to a 1-SD increase in multivariate-
adjusted residuals of the respective lipid level (for non–
HDL-C, LDL-C, and HDL-C) or doubling of triglyceride levels, as
estimated in more than 87 000 samples from Icelandic adults
(eTable 5 in the Supplement).
For all tests, a 2-tailed P < .05 was considered statisti-
cally significant. Analyses were conducted using R version 3.3.2
(R Project for Statistical Computing).
Results
A total of 12 460 Icelandic adults who had been genotyped and
had angiographic data available were identified (Table 1). The
mean (SD) age was 65.1 (10.7) years; 8383 (67.3%) were men,
and 8984 (72.1%) had obstructive CAD (at least 50% diameter
stenosis in at least 1 coronary artery). Among patients with ob-
structive CAD, 5289 (58.9%) had multivessel disease (at least
2-vessel disease or left main disease).
Genetic Scores for Lipid Levels and Obstructive CAD
We assessed whether the genetic scores for levels of non–
HDL-C, LDL-C, HDL-C, and triglycerides were associated with
the presence of obstructive CAD vs no or nonobstructive CAD
(Table 2). The genetic scores for non–HDL-C, HDL-C, LDL-C, and
triglycerides were all associated individually with obstructive
CAD. A genetically predicted 1-SD increase in non–HDL-C lev-
els (38 mg/dL [to convert to millimoles per liter, multiply by
0.0259]) was associated with an 83% higher risk of having ob-
structive CAD (OR, 1.83 [95% CI, 1.63-2.07]; P = 2.8 × 10−23;
Table 2). Similarly, a genetically predicted 1-SD increase in LDL-C
level (34 mg/dL [to convert to millimoles per liter, multiply by
0.0259]) was associated with a 73% higher risk of obstructive
CAD (OR, 1.73 [95% CI, 1.54-1.95]; P = 6.4 × 10−20; Table 2).
The association of the genetic score for non–HDL-C re-
mained significant after accounting for the genetic scores for
HDL-C and triglycerides (OR, 1.75 [95% CI, 1.52-2.01];
P = 3.2 × 10−15), as were the association of the genetic score of
LDL-C after accounting for the genetic scores for HDL-C and
triglycerides (OR, 1.63 [95% CI, 1.44-1.84]; P = 3.0 × 10−15). How-
ever, the genetic score for non–HDL-C conferred additional risk
of obstructive CAD after accounting for the LDL-C genetic score
(OR, 2.13 [95% CI, 1.47-3.10]; P = 6.4 × 10−5) while the asso-
ciation of the LDL-C genetic score was fully explained by the
non–HDL-C genetic score (OR, 0.85 [95% CI, 0.59-1.23]; P = .40
after adjustment for the non–HDL-C genetic score; Table 2).
The genetic score for HDL-C showed a nominal associa-
tion with obstructive CAD when adjusting for the genetic scores
for non–HDL-C and triglycerides (OR, 0.83 [95% CI, 0.72-
0.96]; P = .01; Table 2). The genetic score for triglycerides was
nominally associated with obstructive CAD when adjusting for
the genetic scores for LDL-C and HDL-C (OR, 1.35 [95% CI, 1.06-
1.71]; P = .01) but not after adjustment for the non–HDL-C ge-
netic score (OR, 0.99 [95% CI, 0.76-1.29]; P = .94; Table 2).
Genetic Scores for Lipid Levels and CAD Extent
in Patients With Obstructive CAD
We tested associations with multivessel disease and 3-vessel
disease among patients with obstructive CAD (n = 8984)
(Table 2). A genetically predicted 1-SD increase in non–HDL-C
was associated with a 26% higher risk of multivessel disease
(OR, 1.26 [95% CI, 1.11-1.44]; P = 4.1 × 10−4) and a 47% higher
risk of 3-vessel disease (OR, 1.47 [95% CI, 1.26-1.72];
P = 9.2 × 10−7). The association persisted after adjusting for the
genetic scores for HDL-C and triglycerides (OR, 1.44 [95% CI,
1.21-1.73]; P = 5.8 × 10−5; Table 2). The genetic score for LDL-C
showed similar associations (for multivessel disease: OR, 1.28
[95% CI, 1.12-1.45]; P = 1.9 × 10−4; after adjustment for the
genetic scores for HDL-C and triglycerides: OR, 1.27 [95% CI,
1.11-1.45]; P = 3.5 × 10−4; for 3-vessel disease: OR, 1.43 [95%
CI, 1.23-1.67]; P = 3.8 × 10−6; after adjustment: OR, 1.39 [95%
CI, 1.19-1.63]; P = 4.1 × 10−5) (Table 2). Neither non–HDL-C nor
Table 1. Characteristics of the Coronary Angiography Sample
Characteristic No. (%)
Patients, No. 12 460
Age, mean (SD), y 65.1 (10.7)
Male 8383 (67.3)
Diabetes mellitusa 1467 (11.8)
Hypertensionb 7184 (57.7)
Hyperlipidemiac 6599 (53.2)
Current smoking 2693 (21.6)
Former smoking 6191 (49.7)
Medical history
Myocardial infarction 2221 (18.2)
Percutaneous coronary intervention 330 (2.7)
Coronary artery bypass grafting 659 (5.3)
Angiographic findings
No or nonobstructive coronary artery disease 3476 (27.9)
Obstructive coronary artery disease 8984 (72.1)
1-Vessel diseased 3695 (31.6)
2-Vessel diseased 2462 (21.0)
3-Vessel diseased 2072 (17.7)
Left main disease 755 (6.1)
a Previous diagnosis of diabetes mellitus or the use of antidiabetic medication.
b Previous diagnosis of hypertension or the use of antihypertensive medication.
c Previous diagnosis of hypercholesterolemia or the use of lipid-lowering
medication.
d Without left main disease.
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LDL-C remained significant after adjusting for of the other. The
genetic scores for HDL-C and triglycerides were not associ-
ated with multivessel disease or 3-vessel disease in adjusted
models.
Genetic Scores for Lipid Levels and Coronary Artery Calcium
In addition to angiographic measures of CAD extent, we tested
whether the genetic scores were associated with the pres-
ence and extent of CAC as assessed by cardiac computed to-
mography. A CAC score was available for 4837 individuals on
whom genotype data were available. The mean (SD) age was
58.4 (9.7) years, and 2377 (49.1%) were men. The median CAC
score was 3.8 (range, 0-5223; mean [SD], 134 [353]). Coronary
artery calcium was present in 2598 (53.7%) (CAC score >0), in-
dicating the presence of coronary atherosclerosis, and 1211
(25.0%) had moderate to extensive CAC, defined16 as a CAC
score greater than 100.
Association results for the presence and extent of CAC were
similar to those for angiographic extent of CAD (Table 3). The
genetic score for non–HDL-C was associated with the pres-
ence of CAC (OR, 2.04 [95% CI, 1.70-2.44]; P = 5.3 × 10−15) and
loge-transformed CAC score (0.70 [95% CI, 0.53-0.87];
P = 1.0 × 10−15). The genetic score for non–HDL-C was associ-
ated with the presence and extent of CAC after accounting for
the LDL-C genetic score (OR, 2.06 [95% CI, 1.18-3.60]; P = .01;
loge-transformed CAC score, 0.80 [95% CI, 0.27-1.33]; P = .003,
Table 2. Genetic Scores for Lipid Levels and Angiographic Extent of Coronary Artery Disease
Covariates (Genetic Scores)a
Obstructive Coronary Artery Disease
in Overall Sample (N = 12 460)
Patients With Obstructive Coronary Artery Disease (n = 8984)
Multivessel Disease 3-Vessel Disease
Odds Ratio (95% CI) P Value Odds Ratiob (95% CI) P Value Odds Ratiob (95% CI) P Value
Non–HDL-C 1.83 (1.63-2.07) 2.8 × 10−23 1.26 (1.11-1.44) 4.1 × 10−4 1.47 (1.26-1.72) 9.2 × 10−7
HDL-C 1.74 (1.54-1.98) 3.7 × 10−18 1.26 (1.10-1.45) 6.5 × 10−4 1.46 (1.24-1.72) 4.1 × 10−6
HDL-C and triglycerides 1.75 (1.52-2.01) 3.2 × 10−15 1.31 (1.13-1.52) 4.6 × 10−4 1.44 (1.21-1.73) 5.8 × 10−5
LDL-C 2.13 (1.47-3.10) 6.4 × 10−5 1.01 (0.68-1.50) .97 1.49 (0.93-2.38) .10
LDL-C 1.73 (1.54-1.95) 6.4 × 10−20 1.28 (1.12-1.45) 1.9 × 10−4 1.43 (1.23-1.67) 3.8 × 10−6
HDL-C and triglycerides 1.63 (1.44-1.84) 3.0 × 10−15 1.27 (1.11-1.45) 3.5 × 10−4 1.39 (1.19-1.63) 4.1 × 10−5
Non–HDL-C 0.85 (0.59-1.23) .40 1.27 (0.86-1.87) .24 0.99 (0.62-1.58) .96
HDL-C 0.71 (0.62-0.80) 3.0 × 10−8 0.94 (0.82-1.07) .35 0.87 (0.75-1.02) .09
LDL-C and triglycerides 0.83 (0.72-0.96) .01 0.98 (0.85-1.13) .77 0.99 (0.83-1.17) .89
Non–HDL-C and triglycerides 0.83 (0.72-0.96) .011 0.98 (0.85-1.13) .78 0.99 (0.83-1.18) .90
Triglycerides 1.86 (1.51-2.29) 6.4 × 10−9 1.12 (0.89-1.39) .34 1.45 (1.12-1.89) .005
LDL-C and HDL-C 1.35 (1.06-1.71) .014 1.01 (0.78-1.29) .96 1.28 (0.95-1.73) .10
Non–HDL-C and HDL-C 0.99 (0.76-1.29) .94 0.87 (0.66-1.15) .32 1.05 (0.75-1.46) .78
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; non–HDL-C, non–high-density lipoprotein cholesterol.
SI conversion factor: To convert HDL-C, non–HDL-C, and LDL-C to mmol/L,
multiply by 0.0259.
a In all models, age, age2, sex, diabetes, hypertension, and current smoking and
former smoking status were included as covariates in addition to the genetic
scores. Sample sizes: obstructive coronary artery disease (8984 affected
individuals and 3476 control individuals), multivessel disease (5289 affected
individuals and 3695 control individuals), and 3-vessel disease (2072 affected
individuals and 6157 control participants).
b Odds ratios are scaled to correspond to a 1-SD increase in the respective
cholesterol trait or doubling of triglyceride levels. For non–HDL-C, LDL-C, and
HDL-C, this corresponds to 38 mg/dL (0.97 mmol/L), 34 mg/dL (0.87
mmol/L), and 15 mg/dL (0.38 mmol/L), respectively.
Table 3. Genetic Scores for Lipid Levels and Coronary Artery Calcium
Covariates (Genetic Scores)a
Coronary Artery Calcium Score
Greater Than 0 (n = 4837)
loge-Transformed Coronary Artery
Calcium Scoreb (n = 4837)
Odds Ratioc (95% CI) P Value Effect Size (95% CI) P Value
non–HDL-C 2.04 (1.70-2.44) 5.3 × 10−15 0.70 (0.53-0.87) 1.0 × 10−15
HDL-C 2.05 (1.70-2.48) 4.2 × 10−14 0.67 (0.50-0.85) 1.4 × 10−13
HDL-C and triglycerides 2.07 (1.69-2.55) 3.9 × 10−12 0.70 (0.50-0.90) 3.5 × 10−12
LDL-C 2.06 (1.18-3.60) .01 0.80 (0.27-1.33) .003
LDL-C 1.91 (1.60-2.27) 1.4 × 10−13 0.62 (0.46-0.79) 7.6 × 10−14
HDL-C and triglycerides 1.84 (1.54-2.19) 9.8 × 10−12 0.58 (0.41-0.74) 1.4 × 10−11
Non–HDL-C 0.99 (0.58-1.69) .97 –0.10 (–0.61 to 0.41) .70
HDL-C 0.87 (0.76-0.99) .04 –0.22 (–0.35 to –0.09) .001
LDL-C and triglycerides 1.01 (0.86-1.18) .91 –0.09 (–0.23 to 0.06) .26
Non–HDL-C and triglycerides 1.01 (0.87-1.18) .88 –0.07 (–0.20 to 0.07) .34
Triglycerides 1.43 (1.18-1.74) 3.2 × 10−4 0.37 (0.18-0.56) 1.4 × 10−4
LDL-C and HDL-C 1.26 (1.00-1.57) .047 0.18 (–0.04 to 0.39) .10





SI conversion factor: To convert
HDL-C, non–HDL-C, and LDL-C to
mmol/L, multiply by 0.0259.
a In all models, age, age2, and sex
were included as covariates, in
addition to the genetic scores.
b loge(CAC score + 1).
c Odds ratios and linear regression
coefficients are scaled to
correspond to a 1-SD increase in the
respective cholesterol trait or
doubling of triglyceride levels. For
non–HDL-C, LDL-C, and HDL-C, this
corresponds to 37 mg/dL (0.97
mmol/L), 37 mg/dL (0.87 mmol/L),
and 15 mg/dL (0.38 mmol/L),
respectively.
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respectively), but no association remained for the genetic score
for LDL-C after adjusting for the non–HDL-C genetic score
(Table 3). The genetic scores for HDL-C and triglycerides were
not associated with CAC in adjusted models (Table 3).
Non–HDL-C Genetic Score and Risk of CAD
Previously, we demonstrated a robust association between ge-
netically predicted levels of non–HDL-C and risk of CAD.13 We
sought to validate the association of the current non–HDL-C
genetic score with CAD among Icelandic adults with replica-
tion in the UK Biobank (eMethods and eTable 6 in the Supple-
ment). The non–HDL-C genetic score was associated with in-
creased risk of CAD in the Icelandic population (OR, 1.61 [95%
CI, 1.51-1.71]; P = 1.2 × 10−49; 19 123 affected individuals and
124 461 control individuals) and the UK Biobank (OR, 1.52 [95%
CI, 1.47-1.57]; P = 4.4 × 10−138; 28 110 affected individuals and
380 455 control individuals). Furthermore, the association re-
mained significant after adjustment for the LDL-C genetic score
in both samples (OR, 1.79 [95% CI, 1.47-2.18]; P = 7.8 × 10−9 in
Icelandic adults and OR, 1.81 [95% CI, 1.63-2.01]; P = 5.9 × 10−28
in the UK Biobank), in line with our previous findings.13
Discussion
In this study, we used genetic scores to evaluate the associa-
tions of commonly measured lipid levels with the extent of
coronary atherosclerosis, as assessed by 2 different methods.
The main findings of this study were that (1) genetically pre-
dicted levels of non–HDL-C and LDL-C were consistently as-
sociated with greater extents of coronary atherosclerosis,
(2) the genetic score for non–HDL-C was most significantly as-
sociated with the extent of CAD and provides additional pre-
dictive value beyond the LDL-C genetic score, and (3) geneti-
cally predicted levels of HDL-C and triglycerides were not
significantly associated with the extent of coronary athero-
sclerosis after accounting for the contribution of non–HDL-C.
The non–HDL-C fraction represents the sum of cholesterol
carried by all atherogenic, apolipoprotein B–containing lipo-
proteins. Most non–HDL-C is found within LDL particles (as LDL-
C), while the remainder is carried by triglyceride-rich lipopro-
teins (intermediate-density lipoproteins, very-low-density
lipoproteins, and chylomicron remnants) and, to a lesser de-
gree, lipoprotein(a).27 Recently, we undertook a mendelian ran-
domization analysis that supported a direct involvement of non–
HDL-C, but not triglycerides or HDL-C, in the development of
CAD.13 In that analysis, non–HDL-C was associated with CAD risk
and provided predictive power beyond that of a genetic score
for LDL-C.
In contrast with the previous study, which compared in-
dividuals with CAD to population controls, in the present study,
we studied measures of CAD extent in a population undergo-
ing invasive or noninvasive assessment of CAD. We found that
a genetic score for non–HDL-C was significantly associated with
multiple measures of coronary atherosclerotic burden. In line
with our previous findings, the genetic score for non–HDL-C
was associated significantly with the risk of obstructive CAD
and presence of coronary calcium, even after accounting for
the contribution of LDL-C. This residual association may re-
flect the influence of the cholesterol carried within triglyceride-
rich lipoproteins, also known as remnant cholesterol, which
is a subfraction of non–HDL-C. Accumulating evidence sug-
gests that triglyceride-rich lipoproteins are associated with the
risk of CAD,28-37 most likely because of their content of cho-
lesteryl esters.13,38,39 In line with this, the association of the
genetic score for triglycerides with the extent of angiographic
CAD is fully explained by the genetic score for non–HDL-C.
These findings, summarized in the Figure, together with our
previous results,13 suggest that among the commonly mea-
sured lipid fractions in clinical practice, non–HDL-C may be
the best overall marker of atherogenic lipoproteins and car-
diovascular risk.
Mendelian randomization studies have consistently shown
that HDL-C levels are not likely to contribute to the pathogen-
esis of CAD.13,29,40,41 We observed a nominal association between
the HDL-C genetic score and obstructive CAD after accounting
for the genetic scores for non–HDL-C and triglycerides. How-
ever, there was no association with other measures of angio-
graphic extent of CAD or the extent of coronary calcium. A pos-
sible explanation for these results is residual confounding
due to the pleiotropic effects of multiple HDL-C variants on
other lipid fractions that may not be accounted for in the
adjusted models. Taken together, these results do not sup-
port the hypothesis that HDL-C contributes to the extent of
coronary atherosclerosis.
These findings have implications for predicting potential
cardiovascular benefit from lipid-lowering therapies, espe-
cially with respect to non–HDL-C and triglycerides. Consis-
tent with a potential causal role of non–HDL-C and its major
component LDL-C, reduction in these lipid fractions lowers car-
diovascular risk in a dose-dependent manner.42,43 On the other
hand, trials of triglyceride-lowering therapies have produced



















Color-coded arrowheads denote the
direction of the association of the
respective genetic score with
phenotypes of coronary artery
disease extent. Dashes indicate
nonsignificant associations.
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variable results.44 Thus, it is unlikely that lowering triglycer-
ides per se reduces cardiovascular risk, consistent with a likely
noncausal role in atherogenesis. However, triglyceride-
lowering therapies that also lower non–HDL-C and/or have
nonlipid-associated vascular benefits would be expected to re-
duce cardiovascular risk.
The main strengths of this study include the large sample
size of individuals with genotype, angiographic, and coro-
nary calcium data available and consistent effect sizes of the
genetic scores on different measures of the extent of coro-
nary atherosclerosis. In addition, angiographic data were
obtained from large nationwide angiography registries, reduc-
ing the risk of selection bias.
Limitations
This study has several limitations. We attempted to disen-
tangle the contributions of each lipid level by evaluating the
respective genetic score while adjusting for genetic scores for
other lipid levels. However, unmeasured pleiotropy of the ge-
netic scores may not be accounted for in the adjusted mod-
els. In turn, this may limit the interpretation of causality in the
mendelian randomization analyses. Another limitation is
the use of estimated variant effect sizes on the calculation of
the non–HDL-C genetic score. However, as evident by the high
agreement between calculated and observed effect sizes on
non–HDL-C in Iceland and the UK Biobank, this approach pro-
vides a reliable estimate of non–HDL-C effect sizes.
Conclusions
In this study, we have demonstrated that genetically pre-
dicted levels of non–HDL-C were associated with the extent
of coronary atherosclerosis and provide predictive power be-
yond genetically predicted LDL-C levels. These results sup-
port the notion that non–HDL-C may be a better measure of
the overall burden of atherogenic lipoproteins and cardiovas-
cular risk than LDL-C.
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